Riskpilot← Back to searchSign inGet full accessAtrogi AB
ABActiveOrg 5569258311Tomtebodavägen 6Manufacture of pharmaceutical preparations · NACE 2120Est. 201314 employees
Revenue 2024
SEK 25,3M
EBITDA margin
-148.2%
+12% vs 2023
Equity ratio
77.7%
Financial strength
Net profit 2024
SEK -38,6M
+10% vs 2023
| Revenue | SEK 25,3M | — |
| EBITDA | SEK -37,5M | +12% |
| Net profit | SEK -38,6M | +10% |
| Total assets | SEK 126,9M | +6% |
| Equity | SEK 98,6M | -8% |
| Employees | 14 | — |
Legal name
Atrogi AB
Org number
5569258311
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
13 mars 2013
Share capital
SEK 180 000
Employees
14 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall aktivt utveckla behandlingar, instrument och mediciner inom områdena diabetes och fetma samt där tillhörande områden.
Address
Tomtebodavägen 6
Email
alexandra@atrogi.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 25 338 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −201 | −1 808 | −8 018 | −6 482 | −10 777 | −15 517 | −21 735 | −27 658 | −42 455 | −37 548 |
| Depreciation & amort. | −44 | −169 | −382 | −65 | −136 | −161 | −608 | −839 | −808 | −957 |
| EBIT | −245 | −1 977 | −8 400 | −6 547 | −10 913 | −15 678 | −22 343 | −28 497 | −43 263 | −38 505 |
| Net financials | — | — | −1 | −1 | −2 | −2 | −1 | −1 | 610 | −63 |
| Profit before tax | −245 | −1 977 | −8 401 | −6 548 | −10 915 | −15 680 | −22 344 | −28 499 | −42 654 | −38 568 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −245 | −1 977 | −8 401 | −6 548 | −10 915 | −15 680 | −22 344 | −28 499 | −42 654 | −38 568 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 5 637 | 4 023 | 12 834 | 16 094 | 47 046 | 121 081 | 108 429 | 158 552 | 119 141 | 126 859 |
| Equity | 4 969 | 2 992 | 9 590 | 13 646 | 42 728 | 116 716 | 101 551 | 149 961 | 107 307 | 98 569 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 668 | 1 031 | 3 243 | 2 448 | 4 317 | 4 365 | 6 878 | 8 592 | 11 834 | 28 290 |
| Total debt | 668 | 1 031 | 3 243 | 2 448 | 4 317 | 4 365 | 6 878 | 8 592 | 11 834 | 28 290 |
EBITDA margin
-148.2%
This company
15.8%
Market median
-1038% vs market
20152024
Equity ratio
77.7%
This company
38.2%
Market median
+103% vs market
20152024
Return on equity
-39.1%
This company
18.4%
Market median
-313% vs market
20152024
Net profit margin
-152.2%
This company
8.1%
Market median
-1979% vs market
20152024
Asset turnover
0.20×
This company
1.12×
Market median
-82% vs market
20152024
Debt / equity
0.29×
This company
0.62×
Market median
+53% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BU Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
PB Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
KN Chief Auditor | Chief Auditor | 2022 | — | — |
AK Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
ÅI | Board of Directors | 2022 | — | — |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Atrogi AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Björn Uno Bernhard Westberg | Chief Executive Officer | 0 companies |
| Paul Brian Little | Chief Executive Officer | 0 companies |
| Kent Niklas Jonsson | Chief Auditor | 0 companies |
| Alexandra Kristina Ryding | Chief Executive Officer | 0 companies |
| Mattias Giovanni Fili | Board of Directors | 0 companies |
| Anders Olof Adolf Ekblom | Chairman | 0 companies |
| Robert Sven Christer Taflin | Board of Directors | 0 companies |
| Carl-Johan Spak | Board of Directors | 0 companies |
| Tore Bengtsson | Board of Directors | 0 companies |
| Roger Glen Berlin | Board of Directors | 0 companies |
| Åsa Inde | Board of Directors | 0 companies |
| Sangwoo Lee | Board of Directors | 0 companies |
| Maarten De Chateau | Board of Directors | 0 companies |